As part of NeurologyLive®'s Year in Review, take a look at some of the most listened to and engaging conversations from the Mind Moments™ podcast from this past year.
Publishing new episodes every other Friday, the NeurologyLive® Mind Moments™ podcast features exclusive interviews with leaders in the field of neurology discussing the latest research and disease management strategies across the breadth of the specialty, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, stroke, and more.
It's been yet another big year for the NeurologyLive® Mind Moments™ podcast. By the end of the month, we'll have produced 29 new episodes in 2021—episode 54 is set to premiere this Friday, December 31—featuring more than 45 experts and specialists in the care of patients with neurological disorders, covering topics ranging from newly approved therapies to challenges in patient management to the advances pushing the field forward and more.
Look back on some of the most listened-to episodes of Mind Moments™ from 2021 by clicking the buttons below:
Episode 39, "A Controversial FDA Decision," features insights from a number of individuals in the Alzheimer disease space, including neurologists, psychiatrists, and advocacy partners who share their varying and nuanced opinions on this decision to better understand not only what this approval means for clinical care, but what the downstream effects of it may be. Those individuals, in order of appearance, are Marwan Sabbagh, MD; Anton P. Porsteinsson, MD; David Knopman, MD; Lon Schneider, MD, MS; Robert Howard, MD, MRCPsych; Ian Kremer, JD; and Douglas Scharre, MD.
Episode 41, "Consensus MRI Guidelines for MS," features an exclusive interview with Scott D. Newsome, DO, president, Consortium of Multiple Sclerosis Centers (CMSC), director, Neurosciences Consultation and Infusion Center at Green Spring Station, and associate professor of neurology, Johns Hopkins Medicine; and David Li, MD, FRCPC, professor of radiology, associate member in neurology, and director, Multiple Sclerosis/MRI Research Group, University of British Columbia. The pair spoke about the recent consensus guidelines that were published and developed by the Magnetic Resonance Imaging in Multiple Sclerosis study group; the CMSC working group; and the North America Imaging in Multiple Sclerosis MRI Guidelines working group, in partnership, that marked a massive undertaking in the field of MS care.
Episode 27, "Short, Sudden, Strange, Similar Spells," features an interview with Jacqueline French, MD, director, Translational Research and Clinical Trials in Epilepsy, NYU Grossman School of Medicine. She discussed recently published data from part of the Human Epilepsy Project that suggests the delay in identifying nonvoter seizures can result in injury for the individuals experiencing them, and that earlier identification may prevent this issue.
Episode 31, "The Pipeline Pendulum in Parkinson Disease," features an interview with Stewart Factor, DO, professor of neurology, and director, Jean and Paul Amos Parkinson’s Disease and Movement Disorders Program, Emory University School of Medicine, to discuss the swinging pendulum that is the therapeutic pipeline for Parkinson disease and some of the obstacles that stand in the way of providing optimal care to patients.
Episode 28, "The Multiple Sclerosis Patient Journey," features a portion of our NeurologyLive® Cure Connections series by the same name, put on in partnership with the Consortium of Multiple Sclerosis Centers (CMSC). It features a diverse panel including Patricia K. Coyle, MD, an expert neurologist; Frederick Foley, PhD, a clinical psychologist; Ann Moore, a patient with MS; and her partner, Kathe Zelles. Moderated by June Halper, MSN, MSCN, the group shares their perspectives and experiences on various facets of the disease.
Episode 45, "Small Victories: Advancing Care in Parkinson Disease," features an exclusive interview with Adolfo Ramirez-Zamora, MD, associate professor, program director, and chief, Division of Movement Disorders, University of Florida. He detailed the current state of care for patients with advanced Parkinson disease, the ongoing clinical development of therapies and approaches to the management of the disease, the remaining challenges to address in the clinic, the areas of need around education and awareness, and where the field is headed in the future.
Episode 30, "Cognitive Behavioral Therapy for Insomnia," features an interview with Jennifer Martin, PhD, professor of medicine, University of California-Los Angeles, and a board member of the American Academy of Sleep Medicine (AASM), to discuss the AASM's recent clinical practice guideline update—of which she was a coauthor—that recommends the use of multi-component cognitive behavioral therapy for the treatment of insomnia.
Episode 35, "Highlights From the AAN Annual Meeting," features interviews with Stephanie J. Nahas, MD; Bruce Cree, MD, PhD, MAS; Sana Somani, MD, MBBS; Hubert Fernandez, MD; Daniel Ontaneda, MD, PhD; and Richard Gershon, PhD. Each of them discussed data that they respectively presented at the American Academy of Neurology Annual Meeting. These presentations included novel tools for tracking cognitive decline, analyses of subpopulations of patients with migraine treated with new medicines, the disparities faced by women and Black individuals going through stroke rehabilitation, and more.
Episode 44, "AHA/ASA Updates to the Stroke Care Model" features an exclusive interview with Mitchell S.V. Elkind, MD, MS, MPhil, president, American Heart Association/American Stroke Association (AHA/ASA), and chief, division of neurology clinical outcomes research and population sciences, Columbia University. He discussed the AHA/ASA's recent scientific statement outlining the role of primary care physicians in the poststroke phase of care, as well as the recently updated secondary stroke prevention guidelines.
Episode 36, "Zavegepant and the Gepant Class for Migraine Care," features interviews with Elyse Stock, MD, chief medical officer, Biohaven Pharmaceuticals, and Thomas Shiovitz, MD, director of California Neuroscience Research, to discuss the recently initiated phase 2/3 clinical trial of zavegepant, an oral CGRP-targeting agent for the prevention of migraine developed by Biohaven. The duo discusses how the investigational treatment fits into the gepant class and the impact that the gepants have had on migraine care overall.